Abstract
INSPIRE IVF pcl will begin trading on mai on December 11, 2024. The company offers fertility treatments and regenerative medicine services, with a focus on international patients. Proceeds from the IPO will fund expansion and service quality improvement. Key shareholders post-IPO include Chanachai Joonjiraporn’s group, Puttipong Poomsuwan, and Bundit Anantamongkol. The company’s dividend policy is to pay shareholders at least 50 percent of net profit. For more information, visit the SEC’s website.
INSPIRE IVF pcl Listing on mai
INSPIRE IVF pcl, led by President Prapan Charoenprawatt, will debut on the Market for Alternative Investment (mai) in the Services industry group on December 11, 2024, trading under the symbol “IVF.” The company offers a range of fertility treatment services, including expert consultation, treatment planning, and diagnostic-based assisted conception solutions, such as ICSI and IUI, aimed at maximizing pregnancy success rates.
IVF IPO Details and Future Plans
With a paid-up capital of THB 220 million post-IPO, IVF has a strong business model focusing on fertility treatment services and preventive/regenerative medicine. The company’s IPO shares were offered to various parties, with plans to use the proceeds to expand its branch network, enhance services, and bolster working capital. International certifications attest to its high standards, and major shareholders post-IPO include Chanachai Joonjiraporn’s group, Puttipong Poomsuwan, and Bundit Anantamongkol. Visit the Securities and Exchange Commission’s website for more information on IVF’s prospectus and the company’s official websites for general information.
